SynBiotic SE (XTER:SBX) Debt-to-Asset : 0.11 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is SynBiotic SE Debt-to-Asset?

SynBiotic SE's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.79 Mil. SynBiotic SE's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €2.89 Mil. SynBiotic SE's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was €34.92 Mil. SynBiotic SE's debt to asset for the quarter that ended in Dec. 2023 was 0.11.

SynBiotic SE Debt-to-Asset Historical Data

The historical data trend for SynBiotic SE's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SynBiotic SE Debt-to-Asset Chart

SynBiotic SE Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.01

0.06

0.11

SynBiotic SE Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Dec23
Debt-to-Asset	Get a 7-Day Free Trial				-	0.06	-	0.11	0.11

Competitive Comparison of SynBiotic SE's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, SynBiotic SE's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SynBiotic SE's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SynBiotic SE's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where SynBiotic SE's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

SynBiotic SE Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

SynBiotic SE's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.787	+	2.893)	/	34.918
	=	0.11

SynBiotic SE's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.787	+	2.893)	/	34.918
	=	0.11

SynBiotic SE (XTER:SBX) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

SynBiotic SE Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of SynBiotic SE's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

SynBiotic SE Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SynBiotic SE (XTER:SBX) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Barer Strasse 7, Munich, BY, DEU, 80333

Website

https://www.synbiotic.com

SynBiotic SE is engaged in the development of Phyto-cannabinoids and other herbal compounds concentrated molecules as well as the development of wellness products. The company engages in synthetic production, drug development, cannabinoids, dietary supplements and cosmetic products. Geographical presence in Germany, Austria, UK, Switzerland and Other countries. Majority of its revenue comes from domestic market.

Executives

Daniel Kruse

Geschäftsführender Direktor

SynBiotic SE Headlines

No Headlines